Another round of blood pressure medication is being recalled over concerns it could increase cancer risks.
Lupin Pharmaceuticals Inc. is pulling four lots of Quinapril tablets off shelves in the United States because of the presence of cancer-causing agents.
The Baltimore-based drugmaker issued the voluntary recall on December 21, saying the drugs contain an elevated level of nitrosamine impurity, N-Nitroso-Quinapril, above the acceptable daily intake level.
Nitrosamines are common in water and foods, including cured and grilled meats, dairy products and vegetables, according to the Food and Drug Administration. Everyone is exposed to some level of nitrosamines. However, the FDA says the impurities can increase the risk of cancer if people are exposed to them above acceptable levels over long periods of time.
The recall includes Quinapril Tablets USP 20mg and 40mg, packaged in 90 count bottles. The medications were distributed nationwide to wholesalers, drug chains, mail order pharmacies and supermarkets. The recalled lots include: G102929 (20mg), G100533 (40mg), G100534 (40mg), and G203071 (40mg).
Lupin said it has not received any reports of adverse events linked to any of the treatments and there is no immediate risk to patients taking the medication.
Patients who are taking the meds should consult their doctor about alternative treatment options.
Consumers, wholesalers, distributors and retailers with questions regarding this recall should contact Inmar Rx Solutions, Inc. at (877) 538-8445.
Quinapril is an angiotensin-converting enzyme (ACE) inhibitor indicated for the treatment of hypertension, to lower blood pressure. Another drug maker, New Jersey-based Aurobindo Pharma USA, recalled two lots of the drug in October over the same cancer risk.
Follow KNX News 97.1 FM
Twitter | Facebook | Instagram | TikTok
Related
Related
